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Conclusions: Results exhibited a good synchronization 
between 4D-PET and the system used to register the 
respiratory wave, accurate enough to use it for clinical 
purpose. 
For the 4 types of movement, the cranio-caudal displacement 
between the syringe from the 4D-PET and ANZAI were less 
than 2.30 mm. Moreover, mean difference showed that in 
most of the cases, curves were out of phase. This might lead 
to a systematic error in the tumour position. 
It could be interesting to run more measurements for 
different cycles and 4D-PET acquisitions if we want to modify 
the margins for the GTV due to the use of 4D-PET for tumor 
contouring. 
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Purpose/Objective: The purpose of this work is to 
investigate whether a particular technology can provide 
superior SBRT treatment plans in a real context, 
characterized by different radiation technologies (linac and 
treatment planning systems), and different modality for 
planning (optimization strategies and team experience). 
Materials and Methods: Three inter-comparison studies have 
been designed for prostate, liver, and lung lesions. Five 
contoured CT sets, the dose objective to target and a list of 
constraints for organs at risk, for each anatomical region, 
were sent to the participants. A total of 53 centers across 
Italy joint the studies: 14 for liver metastases, 14 for 
prostate lesions, 25 for lung nodules. Table 1 summarizes the 
irradiation techniques of each center. 
 
 
Results: For the prostate and lung studies, all participants 
were able to achieve the objective of dose to target and to 
respect the constraints on organs at risk. For the liver study, 
5 participants did not comply with the constraint to the 
healthy liver, and 1 center did not achieve the objective of 
dose to the target in one of the five cases. A large difference 
between centers emerges in the three studies, due to the 
differences in the maximum dose and homogeneity accepted; 
no significant correlation between the irradiation techniques 
and dose volume histogram was found.  
Conclusions: Despite the large difference in the irradiation 
technique used, the principal goal of a SBRT approach was 
achieved by all institutions in almost all patients, for both 
dose coverage to target and dose sparing to organs at risk in 
all three regions considered. In our analysis, the optimization 
strategy decided by the planner plays a predominant role 
respect to the technology utilized. Inter-comparison of DVH 
could be a useful tool to standardize treatment planning of 
stereotactic treatments, in particular before starting a 
clinical multi-institution trial. 
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Purpose/Objective: Inhomogeneities around lung tumours 
may reduce the accuracy of dose calculation by the planning 
system. The use of IMRT or VMAT can include small field 
segments which exacerbate these issues. Isotoxic IMRT is a 
multi-centre non-randomised feasibility study of isotoxic dose 
escalation using IMRT, for stage III non-small cell lung cancer 
patients. As part of the pre-trial QA, a dosimetry audit was 
undertaken to verify accurate delivery of the planning 
benchmark case. 
Materials and Methods: An ArcCheck diode array (Sun 
Nuclear) was used to measure fluences from the treatment 
delivery, and apply standard gamma analysis. Half of the 
Multiplug central insert was replaced by lung equivalent 
material (St. Bartholomew’s Hospital, London, UK) to 
simulate an inhomogeneous environment. Point and planar 
dose readings near the interface were acquired using a 
0.125cc ion chamber (PTW Semiflex), and GafChromic EBT3 
film (ISP) (Figure 1). 
 
 
Figure 1. Cross-section through ArcCheck, showing position of 
chamber point and film plane. 
 
Results: 2 pilot centres and 7 trial centres were visited, a 
total of 14 distinct combinations of planning and delivery 
system. Gamma analysis of the entry and exit dose fluence 
showed good agreement, with mean pass rates of 100% (range 
98-100%) and 99% (97-100%) for tolerances of 4%/3mm and 
3%/3mm respectively. Central point doses all agreed within 
±2.4%. Film gamma analysis gave mean pass rates of 96% (88-
100%) and 92% (78-99%) for tolerances of 4%/3mm and 
3%/3mm respectively. These are lower than for the array 
fluences because of proximity to the low density interface. 
Conclusions: This multi-centre audit of complex IMRT 
delivery provides confidence in the accuracy of a range of 
planning and delivery systems in an inhomogeneous 
environment. Along with other aspects of trial QA, it assures 
that trial outcomes will not be undermined by unintended 
variations in delivered doses.  
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Purpose/Objective: By applying the Mean Distance to 
Conformity (MDC) index proposed by Jena et al (1) to the 
dose distribution of a radiotherapy plan, the conformity of 
the 95% isodose line to the Planning Treatment Volume (PTV) 
can be measured, allowing both overdosing of normal tissue 
and underdosing of the target volume to be measured by the 
OverMDC and UnderMDC respectively. The aim of this study 
was therefore to analyse this aspect of treatment planning, 
in addition to volume of PTV and the treatment delivery 
method (3D conformal or Intensity Modulated Radiotherapy), 
and relate to patient outcome. 
Materials and Methods: The OverMDC and UnderMDC of the 
95% isodose line (V95% for 50Gy prescribed dose) to the PTV 
was calculated using a Matlab script based in CERR (2) for 97 
patients from the SCOPE 1 trial (a National Cancer Research 
Institute (NCRI) and Cancer Research UK (CRUK) funded Phase 
II/III two arm trial of definitive chemoradiotherapy (dCRT) in 
oesophageal cancer) (3). Kaplan-Meier and multivariate 
analysis was undertaken in EUCLID (4) with further tests in 
Microsoft Excel and IBM’s SPSS.  
Results: A statistically significant breakpoint in the overall 
survival data, independent of cetuximab, was found 
according to OverMDC metric (0.44cm, p<0.05). This was not 
the case with UnderMDC. There was a statistically significant 
difference in PTV volume either side of the OverMDC 
breakpoint (Mann Whitney p<0.001). There was a statistically 
significant difference in OverMDC value dependent on the 
treatment delivery method (mean IMRT=0.21cm, mean 3D-
CRT=0.41cm Mann Whitney p<0.001). OverMDC did not 
remain significant in a multivariate analysis that included 
age, sex, staging, tumour type, position, PTV volume and 
GTV length. 
Conclusions: We have shown in univariate analysis that a 
patient’s OverMDC has a significant correlation with overall 
survival, independent of Cetuximab. OverMDC is strongly 
related to IMRT and to a lesser extent with PTV volume. We 
recommend careful attention to all aspects of plan quality, 
not just adequate coverage of the PTV.  
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